Downloads: 2 | Views: 103 | Weekly Hits: ⮙2 | Monthly Hits: ⮙2
Comparative Studies | Obstetrics and Gynecology | India | Volume 11 Issue 11, November 2022
A Comparative Study on the Efficacy of Drotaverine Hydrochloride and Valethamate Bromide on Cervical Dilatation in Active Phase of Labour in Tertiary Care Hospital
Dr. Chaganti Vijaya | Dr. Deepa [70]
Abstract: Background: This study was conducted to compare the efficacy of Drotaverine Hydrochloride and Valethamate Bromide on cervical dilatation in active labour, and adverse effects on maternal and fetal outcome. A total number of 300 parturients were studied Group I Control Group-Received no drugs Group II Received intravenous Drotarverine hydrochloride at 3-4 cms cervical dilatation at 2 hourly intervals upto a maximum of 3 doses Group III Received intravenous Valethamate bromide at 3-4 cms cervical dilatation at hourly intervals upto a maximum of 3 doses. Mean duration of active phase of labour in control group was 183.58 ? 72.28 minutes. The duration of active phase is reduced by 96.81 minutes (52% reduction) in Drotaverine group which is statistically significant (p = 0.001) compared with control and 24.58 minutes faster than Valethamate. There was significant difference in rate of Cervical dilatation between the control and other 2 groups (p = 0.001) with Drotaverine achieving 2.72cm/ hr faster dilatation and Valethamate achieving 1.55cm/hr faster dilatation compared to control. Both Drotaverine Hydrochloride and Valethamate had no effect on the uterine contractions. The mean first injections to Delivery interval is significantly reduced in both groups given drugs 48% reductions with Drotaverine and 36% reduction with Valethamate compared to the Active phase delivery internal in Control (p = 0.001). There was no significant shortening of II stage of labour. There was no increase in incidence of instrumental delivery or abdominal delivery in either Drotaverine or Valethamate groups. The incidence of cervical tears was 2% in both drug groups. No case of atonic PPH noted in all 3 groups. Incidence of maternal side effects with drotaverine (3%) is significantly less compared to Valethamate (8%). There was no significant increase in incidence of meconium stained liquor in the drug groups compared to control. All newborns in all 3 groups had Apgar score > 7 at 5 minutes. There was no intrapartum or early neonatal deaths in all the study groups. Conclusion: Drotaverine hydrochloride is a superior cervical dilatation agent significantly reducing the duration of labour without any ill effects on the mother or the fetus. It is significantly better than Valethamate bromide with less side effects due to selective action. Hence it is recommended that Drotaverine Hydrochloride may be given to low risk women in active labour. The promising beneficial effects of Drotaverine hydrochloride are available in obstetric practice and in this study, it has definitely proven to shorten the duration of labour and provide early relief from distress for the labouring woman.
Keywords: cervical dilatation,, active phase
Edition: Volume 11 Issue 11, November 2022,
Pages: 798 - 802